Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermittent Ibrutinib in Advanced CLL (IbruOnOff)
NCT04771507Phase 2Recruiting
- Start
- Feb 2018
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of ibrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL). Started Feb 2018; status: recruiting.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04771507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04771507.